Long-Term IBS Medications and Mortality Risk: What the Latest Research Means for You
Share
Long-Term IBS Medications and Mortality Risk: What the Latest Research Means for You
Enteromed Editorial Team · April 2026 · 6 min read
For millions of people living with irritable bowel syndrome (IBS), managing symptoms is a daily challenge. The condition — marked by abdominal pain, bloating, diarrhoea, constipation, or both — can significantly impact quality of life, work, and mental health. Over the years, a variety of treatments have emerged, from dietary adjustments to prescription medications. But what do we actually know about the long-term safety of these medications? Until now, not much.
Most IBS drug trials last less than a year, leaving important questions about long-term safety unanswered. A landmark study published in April 2026 in Communications Medicine has started to fill that gap. Led by researchers at Cedars-Sinai Health Sciences University, this extensive study examined real-world data on over 650,000 US adults with IBS — making it one of the largest analyses ever conducted on the topic.
The study
What the research looked at
The team analysed electronic health records spanning nearly 20 years (2005–2023) across the United States. The study explored how long-term use of common IBS medications — such as antidepressants, antispasmodics, laxatives, and antidiarrhoeal drugs — was related to all-cause mortality, or death from any reason.
Researchers divided patients into groups based on the medications they took and matched them for age, sex, and underlying health factors to make fair comparisons. They then followed patients for up to 15 years after starting medication, tracking outcomes over time.
Key findings
Three findings every IBS patient should know
Finding 1
Antidepressant use was linked to higher mortality
The study measured a 35% higher risk of death among IBS patients taking antidepressants, compared to those who did not use them. This link was consistent across different antidepressant classes, age, sex, and ethnicity. While the study did not prove that antidepressants cause death, it found a strong and statistically significant association, with long-term use tied to progressively higher risk over time.
Finding 2
Loperamide was associated with twice the mortality risk
For individuals with IBS-D (diarrhoea-predominant IBS), loperamide is a commonly used antidiarrhoeal drug. It is a μ-opioid receptor agonist that slows bowel motility. The study found that people using loperamide had twice the risk of dying compared to IBS-D patients who did not take these medications.
Finding 3
Individual risk remains small in absolute terms
While the numbers sound concerning, experts emphasise that the absolute risk remains relatively low. A “35% increase” translates to a modest 0.6% absolute difference in mortality. This means that while the trend is statistically significant, the average IBS patient is not in immediate danger. However, it may lead doctors to think more carefully about who benefits most from these treatments — and whether safer alternatives are available.
“IBS patients should not panic, but they do need to understand and weigh the small but meaningful risks when considering long-term treatments.”
Dr. Ali Rezaie — Senior Author, Communications Medicine Study · Medical Director, GI Motility Program, Cedars-Sinai
Why this matters
A turning point for personalised IBS care
For decades, doctors and patients have relied on antidepressants and loperamide to manage IBS symptoms because of their effects on pain and motility. But the new evidence suggests the need for more cautious, personalised prescribing. Most IBS drug trials last less than a year — this study followed patients for up to 15 years, making it uniquely powerful in revealing what long-term use actually looks like in real-world populations.
The findings emphasise the importance of routinely reassessing medication needs — and actively exploring safer, non-drug alternatives where they are clinically appropriate.
What patients can do
Practical steps if you take IBS medication
If you are living with IBS and take antidepressants or antidiarrhoeal medications, this research does not mean you should stop your treatment. Instead, consider these proactive steps:
Talk to your doctor
Ask whether your current medication remains the best option, or whether alternatives — including safer non-drug options like Enterosgel — could suit you better.
Do not make abrupt changes
Stopping antidepressants suddenly can worsen both mood and IBS symptoms. Any changes should be guided by your GP or specialist.
Review your overall health
If you have heart conditions, obesity, or depression, ensure these are well-managed — these factors may have influenced mortality outcomes in the study.
Explore non-drug approaches
Enterosgel — a clinically proven, drug-free oral intestinal adsorbent — is available on NHS prescription for IBS-D and has no systemic side effects. Diet modification, stress reduction, mindfulness, gut-directed hypnotherapy, regular exercise, and adequate sleep are all supported by evidence.
A clinically proven drug-free alternative
Enterosgel is a CE Class IIa oral intestinal adsorbent that has been shown in a 440-patient NHS randomised controlled trial to relieve IBS-D symptoms in 76% of patients — with no serious adverse events. It is listed on the NHS Drug Tariff and recommended as a first-line treatment in The Lancet Gastroenterology & Hepatology (2024). Unlike loperamide, it is not an opioid and has no systemic pharmacological effect.
Read the clinical evidence →The takeaway
What this means for the future of IBS treatment
This new research represents a critical step in understanding the long-term safety profile of IBS medications. It highlights that while most treatments are safe in the short term, some — especially antidepressants and opioid-based antidiarrhoeals — may carry a small but significant increase in mortality risk when used long-term.
For most patients, the benefits of controlling debilitating IBS symptoms may still outweigh the potential risks. But these findings underline the importance of individualised care, routine reassessment of medication needs, and the active consideration of safer, evidence-based alternatives — including drug-free options that are now available on NHS prescription.
Looking for a drug-free alternative for IBS-D?
Enterosgel is clinically proven, NHS-prescribable, and recommended in The Lancet. Read the full evidence at enteromed.co.uk/research
View the research →References
- Rezaie A et al. Long-term medication use and mortality in irritable bowel syndrome: a population-based cohort study. Communications Medicine 2026. Cedars-Sinai Health Sciences University.
- Howell CA et al. Double-blinded randomised placebo controlled trial of enterosgel for the treatment of IBS with diarrhoea (IBS-D). Gut 2022;71:2430–2438. doi:10.1136/gutjnl-2022-327293
- Black CJ, Ford AC. Personalised approach to therapy in irritable bowel syndrome. Lancet Gastroenterol Hepatol 2024;9:1162–76.
- NHS. Loperamide (Imodium): about this medicine. nhs.uk